Aptorum Group Limited (APM)
Chart Events
Performance Outlook
| Previous Close | 1.4900 |
| Open | 1.5100 |
| Bid | 1.4000 x 1100 |
| Ask | 1.7100 x 1300 |
| Day's Range | 1.4200 - 1.6700 |
| 52 Week Range | 0.8550 - 2.9400 |
| Volume | |
| Avg. Volume | 111,488 |
| Market Cap | 58.196M |
| Beta (5Y Monthly) | 0.07 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.7150 |
| Earnings Date | Apr 29, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for APM
Related Research
- Aptorum Group LimitedDaily – Vickers Top Buyers & Sellers for 04/19/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat4 months agoArgus Research
- Business Wire
Aptorum Group Limited to Present at the H.C. Wainwright Global Investment Conference, May 23 – 26 2022
NEW YORK & LONDON & PARIS, May 17, 2022--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today announced that Mr. Darren Lui, President and Executive Director of Aptorum Group will present virtually at the H.C. Wainwright Global Investment Conference being held on May 23-26, 2022.
- Simply Wall St.
Here's Why We're Watching Aptorum Group's (NASDAQ:APM) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- Business Wire
Aptorum Group Updates on Data from the Completed Phase 1 Clinical Trial of SACT-1, targeting neuroblastoma
NEW YORK & LONDON & PARIS, May 02, 2022--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ("Aptorum Group" or "Aptorum"), a clinical-stage biopharmaceutical company, is pleased to announce the finalized data from the Phase 1 clinical trial of SACT-1, a repurposed small molecule drug targeting Neuroblastoma and potentially other cancer types.
